Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

gynecomastia/fatigue

リンクがクリップボードに保存されます
ページ 1 から 32 結果

Feminizing Adrenocortical Carcinoma Without Gynecomastia.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Malignant feminizing adrenocortical tumors are exceedingly rare. Their main presentation is gynecomastia. In these estrogen secreting tumors (with or without other adrenocortical hormones) lack of gynecomastia is exceptional as in our case. A 44-year-old man presented with abdominal pain.

Pain, fatigue and depression symptom cluster in survivors of prostate cancer.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Pain, fatigue and depression are common sequelae of a cancer diagnosis. The extent to which these occur together in prostate cancer survivors is unknown. We (i) investigated prevalence of the pain-fatigue-depression symptom cluster and (ii) identified factors associated with

Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND Enzalutamide is an androgen receptor inhibitor with a demonstrated overall survival benefit in metastatic castration-resistant prostate cancer. A phase 2 study of enzalutamide monotherapy in patients with hormone-naïve prostate cancer (HNPC) showed a high response rate for the

Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
OBJECTIVE A phase 2 study of enzalutamide monotherapy in patients with hormone naïve prostate cancer demonstrated high prostate specific antigen response rates at 25 weeks, 1 year and 2 years with minimal effects on total body bone mineral density and favorable safety. In this followup analysis we

Antiandrogen monotherapy: indications and results.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Many patients with prostate cancer for whom hormonal therapy is indicated are still physically and sexually active; quality of life is therefore a vital issue when considering treatment options. Traditional castration-based therapies, although effective, have implications with respect to quality of

Bicalutamide-induced hepatotoxicity: A rare adverse effect.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
METHODS Male, 81 FINAL DIAGNOSIS: Prostate cancer Symptoms: Anorexia • dark urine • joundice • letargy METHODS Casodex Clinical Procedure: - Specialty: Oncology. OBJECTIVE Adverse events of drug therapy. BACKGROUND Bicalutamide is a nonsteroidal anti-androgen used extensively during the initiation

[Anti-thyroid peroxidase in non-neoplastic thyroid pathology].

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Anti-thyroid peroxidase antibodies were prospectively assayed and compared with anti-microsome and anti-thyroglobulin antibodies in 203 patients (188 women, 15 men; mean age 42 +/- 14 years). These patients consulted for hyperthyroidism (n = 42, including 18 with Graves' disease), fumary

Use of cyproterone acetate in prostate cancer.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Cyproterone acetate is a progestational antiandrogen with potent antigonadotropic activity that results in rapid suppression of serum testosterone. Used as a single agent, cyproterone acetate yields a total androgen blockade. It may be combined with low-dose diethylstilbestrol, orchiectomy, or LHRH

[Bronchial carcinoma--an overview].

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
The incidence of lung cancer has exploded in this century. The disease is most commonly diagnosed in the 65-75 year age group but can occur as young as 30 years. Cigarette smoking is usually related to lung cancer in men and the risk of developing lung cancer increases with duration of smoking and

[Primary choriocarcinoma of the bladder: a case report of autopsy].

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
The patient was a 70-year-old male with complaint of macrohematuria at the first visit to our clinic on June 10, 1986. At that time, cystoscopy revealed a thumb sized papillary tumor and a rice sized non papillary tumor, and the biopsy specimen was pathologically diagnosed as undifferentiated

Atypical onset of bicalutamide-induced liver injury.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Anti-androgen therapy is the leading treatment for advanced prostate cancer and is commonly used for neoadjuvant or adjuvant treatment. Bicalutamide is a non-steroidal anti-androgen, used during the initiation of androgen deprivation therapy along with a luteinizing hormone-releasing hormone agonist

[Klinefelter's syndrome: diagnosis and treatment. Case report].

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Klinefelter's syndrome affects 1 in 500 men across all ethnic groups but the diagnosis is often delayed because of substantial variations in clinical presentation. A 26 year-old male came to observation for chronic fatigue. His laboratory data and radiological examination were negative. Examination

Rapid androgen cycling as treatment for patients with prostate cancer.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
OBJECTIVE To investigate the safety and feasibility of rapid androgen cycling for men with progressive prostate cancer. METHODS Schedule 1 included a 4-week induction of androgen depletion, followed by 4-week treatment cycles of a monthly gonadotropin-releasing hormone agonist, testosterone on days

Opioid-induced Endocrinopathy

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Opioid-induced endocrinopathy (OIE) is a condition that affects more Americans than other common comorbid conditions such as heart disease and diabetes combined. It is an important and often unrecognized cause of endocrinopathy, and can result in various clinical manifestations such as sexual

[Androgen deprivation therapy in prostate cancer. Indication and systemic consequences].

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Androgen deprivation therapy (ADT) is effective in prolonging the progression free survival of patients with symptomatic/metastatic prostate cancer (PC). The reduction of clinical symptoms of tumour disease and the reduction of tumour growth and metastatic dissemination is accompanied by systemic
Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge